Novo Nordisk Offers Steady Gains To Go With Dividend
Denmark's Novo Nordisk (NVO), the world's top producer of diabetes drugs, has offered steady capital gains and a dividend too. The stock has quadrupled from its low in April 2009 and is currently in the sixth week of a cup-type base. The pattern is second stage, which gives it a better chance of success than a later-stage pattern. Novo has recovered from a 9% drop Nov. 6, when the Food and Drug Administration warned of possible heart problems with
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here